Figure 1.
Clinical and molecular features of HGBCL-NOS. (A) Heat map of molecular features of the 92 HGBCL-NOS tumors included in the study, grouped by morphological subtype. MYC, BCL2, and BCL6 rearrangement status were determined by FISH. Tumors with a negative (or missing) MYC or BCL2 FISH result for which a rearrangement was identified by sequencing are indicated with a red dot. (B) Comparison of clinical and molecular features in HGBCL-NOS with those of DLBCL-NOS. P values were calculated by the Fisher exact test for comparisons of clinical, FISH, and IHC data, and by χ2 test for refined COO and LymphGen comparisons. (C) Distribution of COO and refined COO subtypes in HGBCL-NOS. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001.
